PRODUCTS & INNOVATION
Abbott Executive Vice President and Chief Financial Officer Brian Yoor explains how strategic shaping created a robust pipeline to fuel faster revenue growth.
Mar 15 2019
Abbott's leadership has evolved the company prudently by investing in its own fast-growing medical technologies and by acquiring the right set of devices in the most promising areas of healthcare. The result: A global player with the richest pipeline of new offerings in its recent history, and investors are noticing.
The drivers behind the forecasted revenue growth of 6.5-7.5 percent this year include contributions from all Abbott businesses, said Brian Yoor, chief financial officer and executive vice president, at a Barclays investor conference. Abbott's FreeStyle Libre continuous glucose monitoring system, its Alinity diagnostics platforms and its fast-growing Mitraclip treatment to repair heart valves are just some of the technologies that are making a big impact.
"It's just an exciting time for Abbott, and it's exciting to have clear line of sight of where we're going and how we're getting there," Yoor said. Hear more of his remarks here.
Small Tech, Big Impact
Abbott Q2 Earnings Beat Expectations
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.